Curis, Inc. (NASDAQ:CRIS)‘s stock had its “buy” rating restated by stock analysts at Cowen and Company in a research report issued to clients and investors on Wednesday. The analysts wrote, “We expect interest in Curis’ pipeline of innovative oncology compounds to heighten.”” Several other research analysts also recently commented on the company. Zacks Investment Research […]
